{"api":{"name":"api.sb","description":"Business-as-Code surface for Startups.Studio","home":"https://api.sb","docs":"https://api.sb/docs","version":"1.0.0"},"$context":"https://api.sb/$context","$type":"FoundingHypothesis","$id":"https://api.sb/founding-hypotheses/fh%3Aw2-investigational-new-drug-application-to-fda-submission-regulatory-affairs-mgr-clinical-protocol%3At-td%3Av1","links":{"self":"https://api.sb/v1/founding-hypotheses/fh%3Aw2-investigational-new-drug-application-to-fda-submission-regulatory-affairs-mgr-clinical-protocol%3At-td%3Av1","canonical":"https://api.sb/founding-hypotheses/fh%3Aw2-investigational-new-drug-application-to-fda-submission-regulatory-affairs-mgr-clinical-protocol%3At-td%3Av1","pool":"https://api.sb/v1/founding-hypotheses"},"foundingHypothesis":{"id":"fh:w2-investigational-new-drug-application-to-fda-submission-regulatory-affairs-mgr-clinical-protocol:t-td:v1","lens":"HeadlessSaaS","type":"founding-hypothesis","click":{"rubricScores":{"C8_lensFit":0,"C7_magicLensFit":0,"C4_competitorHonesty":1,"C6_crossSlotCoherence":1,"C1_customerSpecificity":1,"C2_problemFrictionRealism":1,"C9_killCriteriaAttestability":1,"C3_approachEngineCoverability":1,"C5_differentiationLoservilleEscape":1},"upperRightLoserville":true},"cellRef":{"id":"work-contexts.org.ai/w2-investigational-new-drug-application-to-fda-submission-regulatory-affairs-mgr-clinical-protocol","stableHash":"wcc:regulatory-affairs-mgr:investigational-new-drug-application-to-fda-submission:clinical-protocol:v1"},"problem":{"slotStatement":"The RA Manager spends weeks reconciling the clinical protocol, Investigator's Brochure, and Module 2.5 clinical overview by hand to ensure every efficacy/safety claim traces to a source document before the IND ships, and a single unsourced claim or version-drift inconsistency triggers an FDA Information Request that delays the 30-day clock."},"approach":{"oneSentence":"A protocol-bound claim-citation ledger that cross-checks every assertion in Module 2.5 and the IND cover letter against the clinical protocol, IB, and CMC source docs, certifies each claim with a review-ready citation trail, and escalates unresolved or drifted claims to the RA Manager before submission lock."},"customer":{"icpShape":"VP of Regulatory Affairs at US-based venture-backed biotech (Series B–C, 50–300 employees, single lead program approaching first-in-human) preparing an initial IND submission to CDER, where the buyer is the VP of Regulatory Affairs and the daily user is the Regulatory Affairs Manager assembling the Module 2/5 clinical protocol sections","beachheadShape":"EarlyAdopterJTBD — first-time-IND venture-backed biotechs filing a single lead program with CDER in the next 6 months"},"archetype":"startup-archetypes.org.ai/HeadlessSaaS-MarketplaceClearing","beachhead":"EarlyAdopterJTBD — first-time-IND venture-backed biotechs filing a single lead program with CDER in the next 6 months","competitors":{"substitutes":[{"name":"Veeva Vault RIM (Submissions + RIM Registrations)","category":"incumbent"},{"name":"Certara GlobalSubmit / D360 publishing stack","category":"incumbent"},{"name":"MasterControl + manual RA analyst review in Word/Excel","category":"status-quo"},{"name":"IQVIA regulatory consultant contract RA support","category":"human alternative"}]},"studioThesis":"T-TD","killThreshold":{"K":10,"M":30,"N":7,"rubricItemSet":["C1_customerSpecificity","C2_problemFrictionRealism","C3_approachEngineCoverability","C4_competitorHonesty","C5_differentiationLoservilleEscape","C6_crossSlotCoherence","C7_magicLensFit","C8_lensFit","C9_killCriteriaAttestability"],"verdictPolicy":"all-load-bearing-pass-and-overall-ge-X","loadBearingItemSet":["C1_customerSpecificity","C2_problemFrictionRealism","C3_approachEngineCoverability","C4_competitorHonesty","C5_differentiationLoservilleEscape","C6_crossSlotCoherence","C9_killCriteriaAttestability"],"verdictPolicyVerbatim":"KILL unless every load-bearing rubric item passes per workbook AND overall pass-rate ≥ 7/9 (CASCADE.md §4 Stage 9 commit threshold)."},"lifecycleState":"Active","differentiation":{"twoByTwo":{"xAxis":"Claim-to-source traceability (document-management foldering ↔ per-sentence citation back to protocol/IB line)","yAxis":"Regulatory authority depth (general life-sciences content platform ↔ CDER IND-specific review rubric baked in)","winningQuadrant":"per-sentence claim citations bound to CDER IND review criteria, surfaced inline in the Module 2.5 draft the RA Manager is editing","loservilleEscape":true,"loservilleQuadrant":"Veeva Vault RIM-style folder-and-metadata management that stores the protocol and IB as PDFs but leaves the RA Manager to manually verify whether each Module 2.5 claim is consistent with its source"}},"unmetRequirements":[],"pricingArchitecture":"usage-meter"},"actions":{},"options":{},"relationships":{"runtimeUnit":"https://api.sb/v1/runtime-units?startupRef=startup%3Afh%3Aw2-investigational-new-drug-application-to-fda-submission-regulatory-affairs-mgr-clinical-protocol%3At-td%3Av1","brand":"https://api.sb/v1/brands?startupId=startup%3Afh%3Aw2-investigational-new-drug-application-to-fda-submission-regulatory-affairs-mgr-clinical-protocol%3At-td%3Av1","listing":"https://api.services/listings?foundingHypothesisRef=fh%3Aw2-investigational-new-drug-application-to-fda-submission-regulatory-affairs-mgr-clinical-protocol%3At-td%3Av1","cell":"https://api.sb/v1/cells/work-contexts.org.ai/w2-investigational-new-drug-application-to-fda-submission-regulatory-affairs-mgr-clinical-protocol","thesis":"https://api.sb/v1/theses/T-TD"},"meta":{"level":"L0","scopes":[]},"user":{"requestId":"a0575bd7ed332e5c","edgeLocation":"a0575bd7ed332e5c","geo":{"country":"US"},"ua":{"browser":"Claude"}},"references":{"total":0,"limit":25,"page":1,"links":{"self":"https://api.sb/v1/founding-hypotheses/fh%3Aw2-investigational-new-drug-application-to-fda-submission-regulatory-affairs-mgr-clinical-protocol%3At-td%3Av1/references"},"items":[]}}